interesting study

Hi,

There is a new study executed by a research group at Karolinska, Stockholm, where the combination of PSA and Thymidine kinase 1 was used to predict aggressiveness of prostate cancer. The combined biomarker TK1+PSA predicts up to 10 years difference in overall survival in men with PCa. This could be very valuable, for example, in the choice between active surveillance and radical surgery. A blood sample is more convenient for the patients than biopsies, and it may reduce unnecessary suffering for patients, and costs for healthcare.

The article was published in the International Journal of Molecular Science some days ago: Prediction of overall survival by thymidine kinase 1 combined with prostate specific antigen in men with prostate cancer

https://www.mdpi.com/1422-0067/24/6/5160#

Kind regards